Rutger Koornstra
Overview
Explore the profile of Rutger Koornstra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kennedy O, Kicinski M, Valpione S, Gandini S, Suciu S, Blank C, et al.
Eur J Cancer
. 2022 Feb;
165:97-112.
PMID: 35220182
Background: β-adrenergic receptors are upregulated in melanoma cells and contribute to an immunosuppressive, pro-tumorigenic microenvironment. This study investigated the prognostic and predictive value of β-adrenoreceptor blockade by β-blockers in the...
2.
Joosten S, Wellenstein M, Koornstra R, van Rossum A, Sanders J, van der Noort V, et al.
NPJ Breast Cancer
. 2021 Oct;
7(1):138.
PMID: 34671036
Window studies are gaining traction to assess (molecular) changes in short timeframes. Decreased tumor cell positivity for the proliferation marker Ki67 is often used as a proxy for treatment response....
3.
Bottomley A, Coens C, Mierzynska J, Blank C, Mandala M, Long G, et al.
Lancet Oncol
. 2021 Apr;
22(5):655-664.
PMID: 33857414
Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with...
4.
Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S, et al.
Lancet Oncol
. 2021 Apr;
22(5):643-654.
PMID: 33857412
Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab...
5.
Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S, et al.
J Clin Oncol
. 2021 Jan;
39(8):944-946.
PMID: 33492998
No abstract available.
6.
Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S, et al.
J Clin Oncol
. 2020 Sep;
38(33):3925-3936.
PMID: 32946353
Purpose: We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III...
7.
van Wilpe S, Koornstra R, Den Brok M, De Groot J, Blank C, de Vries J, et al.
Oncoimmunology
. 2020 Mar;
9(1):1731942.
PMID: 32158624
Lactate dehydrogenase (LDH) levels are inversely related with response to checkpoint inhibitors. Elevated LDH levels are the product of enhanced glycolytic activity of the tumor and tumor necrosis due to...
8.
Eggermont A, Kicinski M, Blank C, Mandala M, Long G, Atkinson V, et al.
JAMA Oncol
. 2020 Jan;
6(4):519-527.
PMID: 31895407
Importance: Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown. Objective: To investigate the association between irAEs and recurrence-free survival (RFS) in...
9.
Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S, et al.
Eur J Cancer
. 2019 Jun;
116:148-157.
PMID: 31200321
Background: The American Joint Committee on Cancer-8 (AJCC) classification of melanoma was implemented in January 2018. It was based on data gathered when checkpoint inhibitors were not used as adjuvant...
10.
Beelen K, Opdam M, Severson T, Koornstra R, Vincent A, Wesseling J, et al.
BMC Cancer
. 2018 Jul;
18(1):761.
PMID: 30041599
Background: Controversy exists for the use of Ki67 protein expression as a predictive marker to select patients who do or do not derive benefit from adjuvant endocrine therapy. Whether other...